InterventionsHuman trial

The Confidence Trial—Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes

ADA Scientific Sessions 2025 Abstract

The paper

Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink,

Johannes F. Mann, Janet B. McGill, Amy K. Mottl, Julio Rosenstock, Peter R Rossing, Muthiah Vaduganathan, Meike Daniela Brinker, Charlie Scott, Linda C. Li, Katja Rohwedder,

Masaomi Nangaku

Indianapolis

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Late-breaking 1863-LB

doi.org/10.2337/db25-1863-lb

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
The American Journal of Cardiology · 8 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026